Isis Pharmaceuticals, Eli Lilly deal

In December, Isis re-acquired rights to ISIS-EIF4ERx (formerly LY2275796) from Lilly as part of strategy to focus on internal cancer programs. The pharma has an option to re-acquire rights prior to ...